SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong Sells 8,500 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $7.66, for a total value of $65,110.00. Following the completion of the sale, the chairman directly owned 3,435,822 shares in the company, valued at $26,318,396.52. This represents a 0.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.61, for a total transaction of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.23, for a total transaction of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total value of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20.

SOPHiA GENETICS Stock Down 0.1%

Shares of NASDAQ SOPH traded down $0.01 during mid-day trading on Monday, reaching $7.86. The company had a trading volume of 309,330 shares, compared to its average volume of 261,716. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The firm has a 50 day simple moving average of $7.03 and a two-hundred day simple moving average of $5.69. The stock has a market cap of $659.38 million, a P/E ratio of -6.83 and a beta of 0.98. SOPHiA GENETICS SA has a 52-week low of $3.12 and a 52-week high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. Sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research upped their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, HC Wainwright boosted their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently bought and sold shares of SOPH. Maven Securities LTD acquired a new position in SOPHiA GENETICS in the 2nd quarter valued at $866,000. AXQ Capital LP acquired a new stake in shares of SOPHiA GENETICS in the 2nd quarter worth $119,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter valued at about $9,809,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of SOPHiA GENETICS during the second quarter worth about $567,000. Finally, Royal Bank of Canada increased its stake in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares during the period. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.